Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
BMC Biotechnol ; 13: 6, 2013 Jan 28.
Artículo en Inglés | MEDLINE | ID: mdl-23356604

RESUMEN

BACKGROUND: Plasmid-based overexpression of genes has been the principal strategy for metabolic engineering. However, for biotechnological applications, plasmid-based expression systems are not suitable because of genetic instability, and the requirement for constant selective pressure to ensure plasmid maintenance. RESULTS: To overcome these drawbacks, we constructed an Escherichia coli lycopene production strain that does not carry a plasmid or an antibiotic marker. This was achieved using triclosan-induced chromosomal evolution, a high gene copy expression system. The engineered strain demonstrated high genetic stability in the absence of the selective agent during fermentation. The replacement of native appY promoter with a T5 promoter, and the deletion of the iclR gene in E. coli CBW 12241 further improved lycopene production. The resulting strain, E. coli CBW 12241(ΔiclR, PT5-appY), produced lycopene at 33.43 mg per gram of dry cell weight. CONCLUSIONS: A lycopene hyper-producer E. coli strain that does not carry a plasmid or antibiotic marker was constructed using triclosan-induced chromosomal evolution. The methods detailed in this study can be used to engineer E. coli to produce other metabolites.


Asunto(s)
Carotenoides/biosíntesis , Cromosomas/metabolismo , Escherichia coli/metabolismo , Evolución Molecular , Biomasa , Proteínas de Escherichia coli/genética , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Técnicas de Inactivación de Genes , Licopeno , Plásmidos/genética , Plásmidos/metabolismo , Regiones Promotoras Genéticas , Transactivadores/genética , Triclosán/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA